Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an updated issuance date for the company’s first quarter 2024 financial results. The Company requires additional time to work through accounting and discontinued operations matters primarily as a result of entering into a definitive agreement in March 2024 to divest assets relating to the Company’s Enabling Services segment.

Fortrea will now release its first quarter 2024 financial results before the market opens on Monday, May 13, 2024, rather than on Tuesday, May 7, 2024, as previously announced. The company will host a conference call at 8:00 am ET on the date of release to review its financial results and conduct a question-and-answer session.

To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea Investor Relations website.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, consulting services, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 18,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.  

Fortrea Contacts
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

Staff

Recent Posts

Safe Supply Streaming Co Ltd. to Attend Great Plains Tribal Leaders’ Health Board in South Dakota

Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY)…

57 minutes ago

Predictmedix AI Inc – 2025 Year End Corporate Update

A Defining Year Positioning Predictmedix AI at the Convergence of Quantum, AI, and HealthcareToronto, Ontario--(Newsfile…

57 minutes ago

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica…

3 hours ago

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica…

3 hours ago

Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma

Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction with the 3rd…

3 hours ago